Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

PET Imaging Biomarker Collaboration Established for Investigational BACE Inhibitor Clinical Development Program

By BiotechDaily International staff writers
Posted on 14 Jan 2013
Merck (Whitehouse Station, NJ, USA), known as MSD outside the United States and Canada), and GE Healthcare (Chalfont St. Giles, UK) have initiated a clinical study collaboration, license, and supply agreement for use of [18F]flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck’s development of MK-8931, a unique oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck’s chief investigational candidate for Alzheimer’s disease (AD).

Accumulation of beta amyloid in the brain is a pathologic characteristic related to Alzheimer’s disease. Currently, AD is diagnosed by clinical examination (i.e., physical, medical history neurologic, psychiatric, and neuropsychologic exams, laboratory tests and magnetic resonance imaging [MRI] or computed tomography [CT] scan). An AD diagnosis can only be validated through histopathologic identification of characteristic features, including beta amyloid plaques, in postmortem brain samples.

“There is a serious unmet need for a reliable method for measuring beta amyloid deposits to help physicians diagnose Alzheimer’s disease at its different stages and study its progression,” said Darryle Schoepp, PhD, senior vice president, head of neuroscience and ophthalmology, Merck Research Laboratories. “This agreement will allow us to employ an investigational imaging agent to help identify patients who might benefit from an antiamyloid therapy and enable clinical evaluation of our lead BACE inhibitor candidate for Alzheimer’s disease, MK-8931.”

Under the agreement, GE Healthcare will supply [18F]flutemetamol to help select patients for clinical trials and evaluate this investigational agent as a companion diagnostic tool. A joint Merck and GE Healthcare imaging advisory committee will oversee the planned imaging studies.

“In clinical trials, [18F]flutemetamol demonstrated consistent performance in the visual detection of beta amyloid in the brain when compared with histopathology data,” said Jonathan Allis, general manager, PET, GE Healthcare medical diagnostics. “[18F]flutemetamol imaging has the potential to be part of a larger diagnostic workup that may help doctors rule out Alzheimer’s disease by reliably showing the absence of amyloid deposits in patients with unexplained loss of cognitive function.”

Merck is advancing several novel programs involved in AD research, including candidates designed to modify disease progression as well as improve symptom control. Merck’s lead candidate in disease modification is MK-8931, an investigational oral BACE inhibitor.

Results of phase I clinical studies demonstrated that MK-8931 can reduce cerebral spinal fluid (CSF) beta amyloid by greater than 90% in healthy study participants without dose-limiting side effects. Based on these findings, Merck has established a global, multicenter phase II/III clinical trial, called EPOCH (please see Related Links below), to evaluate the safety and effectiveness of MK-8931 versus placebo in patients with mild-to-moderate AD.

[18F]flutemetamol is an investigational PET imaging agent being developed by GE Healthcare for the detection of beta amyloid deposits in the brain. Pooled results from phase III brain autopsy and biopsy studies showed a strong concordance between [18F]flutemetamol images and AD-associated beta amyloid brain pathology. Phase III studies demonstrated [18F]flutemetamol visual identification of beta amyloid with a majority read sensitivity of 86% and specificity of 92%.

AD is a debilitating and ultimately fatal disease that progressively destroys neurons in the brain, leading to a deterioration of cognitive function. The symptoms include loss of memory that advances into behavioral alterations, changes in thinking and reasoning skills that have an effect in daily activities, and dementia. AD is the most common cause of dementia, accounting for approximately 50%–75% of the estimated 35-million dementia cases worldwide.

Whereas the precise cause of AD remains unknown, a current predominant hypothesis ascertains that AD occurs due to the accumulation of beta amyloid proteins in the brain. Beta amyloid precursor protein site cleaving enzyme (BACE) is believed to be a major enzyme in the production of beta amyloid peptide. Study findings suggest that suppressing BACE decreases the generation of beta amyloid and may therefore decrease amyloid plaque formation and alter the course of disease progression.

Related Links:

Merck
EPOCH Trial
GE Healthcare



Channels

Genomics/Proteomics

view channel
Image: The bone marrow of mice with normal ether lipid production (top) contains more white blood cells than are found in the bone marrow of mice with ether lipid deficiency (bottom) (Photo courtesy of Washington University School of Medicine).

Inactivating Fatty Acid Synthase Reduces Inflammation by Interfering with Neutrophil Membrane Function

The enzyme fatty acid synthase (FAS) was shown to regulate inflammation by sustaining neutrophil viability through modulation of membrane phospholipid composition. Neutrophils are the most abundant... Read more

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more

Business

view channel

Biotech Acquisition Designed to Accelerate the Development and Marketing of Immunosequencing Applications

Adaptive Biotechnologies Corp. (Seattle, WA, USA), a developer of next-generation sequencing (NGS) to profile T-cell and B-cell receptors, has acquired of Sequenta, Inc. (South San Francisco, CA, USA), which is expected to expedite and expand the use of innovative immunosequencing technology for researchers and clinicians... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.